Is Buying Tracon Pharmaceuticals Inc (NASDAQ:TCON) Here Good Idea?

September 30, 2018 - By Megan Stone

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Logo

The stock of Tracon Pharmaceuticals Inc (NASDAQ:TCON) registered an increase of 11.92% in short interest. TCON’s total short interest was 205,700 shares in September as published by FINRA. Its up 11.92% from 183,800 shares, reported previously. With 119,900 shares average volume, it will take short sellers 2 days to cover their TCON’s short positions. The short interest to Tracon Pharmaceuticals Inc’s float is 1.42%.

The stock decreased 4.65% or $0.1 during the last trading session, reaching $2.05. About 83,881 shares traded or 0.10% up from the average. TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) has declined 34.33% since September 30, 2017 and is downtrending. It has underperformed by 49.95% the S&P500.

TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration , and fibrotic diseases. The company has market cap of $61.17 million. The Company’s lead product candidate is TRC105, an endoglin antibody, which is in Phase III clinical trials for angiosarcoma; randomized Phase II clinical trials for renal cell carcinoma; Phase II clinical trials for soft tissue sarcoma; Phase II clinical trials for gestational trophoblastic neoplasia; Phase I/II clinical trials for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trials for breast cancer; and Phase I/II clinical trials for wet AMD. It currently has negative earnings. The companyÂ’s other product candidates comprise TRC102, a small molecule that is in Phase II clinical trials for mesothelioma, Phase II clinical trials for glioblastoma, Phase I clinical trial for solid tumors and lymphomas, as well as Phase I clinical trial for lung cancer; and TRC253, a small molecule high affinity competitive inhibitor of wild type androgen receptor (AR) and multiple AR mutant receptors that is in Phase I/II clinical trials for the treatment prostate cancer.

Another recent and important TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) news was published by Seekingalpha.com which published an article titled: “TRACON Pharmaceuticals announces publication of Phase 1b results for TRC105 in combination with Inlyta in patients …” on September 10, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: